US healthcare stocks remained market heavyweights in 2025, driven by blockbuster weight-loss drugs, demographic demand, and innovation. Eli Lilly led the sector after briefly crossing $1 trillion in value, while Johnson & Johnson and AbbVie posted solid gains. UnitedHealth lagged amid audits and regulatory scrutiny, highlighting growing policy and pricing pressures.